Diagnostics firm finalizes Matritech acquisition

January 31, 2008

Inverness Medical Innovations, Inc. has finalized its acquisition of Matritech, Inc., the manufacturer of the NMP22 BladderChek Test.

Inverness Medical Innovations, Inc. has finalized its acquisition of Matritech, Inc., the manufacturer of the NMP22 BladderChek Test.

The BladderChek is a point-of-care test cleared by the FDA for both the diagnosis and monitoring of bladder cancer. Inverness is an international developer of point-of-care diagnostics related to infectious disease, cardiology, oncology, drugs of abuse, and women’s health.

“Matritech’s expertise in the development of protein-based diagnostic products for the early detection of cancer is a terrific addition to the Inverness portfolio of products and capabilities, said Ron Zwanziger, CEO of Inverness.